Telix Resubmits FDA Application for Brain Cancer Imaging Agent Pixclara

Telix resubmits FDA application for brain cancer imaging agent Pixclara

Telix Pharmaceuticals (ASX: TLX) has resubmitted its New Drug Application to the US Food and Drug Administration for TLX101-Px (Pixclara), an investigational PET imaging agent designed to help characterise recurrent or progressive glioma from treatment-related changes in both adult and paediatric patients. The Telix Pixclara FDA resubmission was lodged on 16 March 2026 and addresses a Complete Response Letter the company received on 28 April 2025.

The company has stated it believes the additional data and statistical analysis, combined with the primary data set from the original submission, appropriately addresses the FDA’s concerns raised in the Complete Response Letter. This confidence follows a Type A meeting and ongoing consultation with the FDA. TLX101-Px holds both Orphan Drug designation (granted October 2020) and Fast Track designation (granted April 2024), regulatory acknowledgements that reflect the FDA’s recognition of significant unmet medical need.

The resubmission represents a material regulatory catalyst for Telix. Despite 18F-FET imaging already being included in international clinical practice guidelines for glioma imaging, there is currently no FDA-approved targeted amino acid PET agent commercially available in the US for adult and paediatric brain cancer imaging, positioning Pixclara as a potential first-in-class product in this space.

What is Pixclara and why does brain cancer imaging matter?

TLX101-Px (Pixclara, Floretyrosine F 18 or 18F-FET) is a PET imaging agent that helps doctors distinguish between actual cancer recurrence and changes caused by treatment in brain scans. After surgery, radiation, and chemotherapy, brain scans often show changes that may look like tumour regrowth but could actually be treatment effects. Accurately differentiating between these two scenarios is critical for determining the correct patient management strategy.

18F-FET is already included in international clinical practice guidelines for glioma imaging, reflecting its established role in other markets. However, the US currently lacks an FDA-approved targeted amino acid PET agent for this purpose, creating a significant gap between clinical practice recommendations and commercially available tools.

The FDA’s Fast Track designation is designed to facilitate development and expedite review of drugs treating serious conditions with unmet need. The aim is to bring important new diagnostics to patients earlier in the regulatory process.

The glioma market and commercial opportunity

Gliomas are highly infiltrative tumours affecting brain tissue and represent the most common form of central nervous system neoplasm originating from glial cells. They account for approximately 30% of all brain and CNS tumours and 80% of all malignant brain tumours. In the US, gliomas are diagnosed at a rate of 6 cases per 100,000 people annually.

Glioblastoma (GBM), a high-grade glioma, is the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the US. The standard treatment comprises surgical resection followed by combined radiotherapy and chemotherapy. Despite this intensive treatment approach, recurrence occurs in almost all patients, with expected survival duration of 12 to 15 months from diagnosis.

The near-universal recurrence rate creates ongoing demand for accurate imaging to guide post-treatment management decisions. Telix has established an Expanded Access Programme for TLX101-Px, indicating existing patient demand for this imaging option.

Maggie Haynes, Executive Director, Head for the Cure Foundation

“Our community is encouraged by the FDA’s ongoing engagement and guidance to the sponsor and support for the Expanded Access Program for TLX101-Px. We are hopeful of an expedited review, so this important and proven imaging option can become available to those who urgently need it.”

Pixclara’s strategic fit within Telix’s brain cancer pipeline

TLX101-Px targets membrane transport proteins known as LAT1 and LAT2 (L-type amino acid transporters 1 and 2). This targeting mechanism positions Pixclara as a potential companion diagnostic for Telix’s therapeutic candidate TLX101-Tx (iodofalan 131I), which targets LAT1 and is currently under investigation in the pivotal IPAX-BrIGHT study.

The theranostic pairing follows Telix’s core business model of developing matched imaging and therapy products:

1. TLX101-Px (Pixclara): Diagnostic imaging agent targeting LAT1/LAT2 for patient characterisation
2. TLX101-Tx (iodofalan 131I): Therapeutic candidate targeting LAT1 under investigation in IPAX-BrIGHT (NCT07100730)
3. Companion diagnostic potential: Pixclara could serve to identify patients most likely to benefit from TLX101-Tx therapy

This integrated approach mirrors Telix’s existing commercial success with its PSMA-targeted imaging products, where diagnostic tools support therapeutic development and patient selection.

What happens next and regulatory timeline

With the NDA resubmission lodged, the FDA review clock restarts. Fast Track designation is designed to expedite review of products addressing serious conditions with unmet need, though the company has not speculated on an exact approval timeline.

Dr David N. Cade, Group Chief Medical Officer

“We appreciate the FDA’s recognition of the critical unmet need to improve the diagnosis and management of glioma, particularly in the post-treatment setting. Our resubmission is supported by an extensive and compelling data set – particularly so for an orphan indication.”

Orphan Drug designation provides potential market exclusivity benefits upon approval, whilst Fast Track status may enable expedited review. The combination of these designations reflects FDA recognition of both the rarity of the condition and the unmet medical need.

Telix operates as a global biopharmaceutical company focused on therapeutic and diagnostic radiopharmaceuticals, with international operations across the US, UK, Brazil, Canada, Europe, and Japan. The company has demonstrated regulatory and commercialisation capability through existing approved products including Illuccix and Gozellix, both PSMA-PET imaging agents. TLX101-Px and TLX101-Tx have not received marketing authorisations in any jurisdiction.

Don’t Miss the Next Healthcare Breakthrough

Join 20,000+ investors getting FREE breaking ASX news delivered to your inbox within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive expert coverage the moment market-moving healthcare announcements hit the ASX.